menu

Quintiles Library

Precision Enrollment
Featured Video
Show Filters
White Paper
In this, the final of our three-part series of reports exploring strategic growth models in Asia Pacific, we examine the opportunities and challenges faced by local companies with global growth aspirations.In this series:Affordable TherapiesInnovation the Asia way
Explore More
Article
Asia's socioeconomic growth and increased population longevity is causing an epidemiological shift in the health issues and health care challenges. Historically, infectious diseases have attracted the most attention and research dollars, but the region is now seeing a rise in chronic disorders, previously more common in Western nations, including heart disease and...
Explore More
Article
Similar to generics, biosimilars offer the potential to change the landscape of the biopharma industry by bringing patients more access to medicines around the world and new revenue streams to the marketing authorization holders (MAHs) who bring these products to market. With many patents of branded biologics expiring, the biosimilars industry holds incredible growth...
Explore More
White Paper
This paper provides an overview of how biosimilars are regulated and outlines a stepwise approach, including how to plan and design smarter biosimilar clinical trials, to overcome complex regulatory hurdles.
Explore More
Brochure
クインタイルズは、先端医療・再生医療分野において安全で有益な製品が一日でも早く承認・上市されるために開発支援を行い、人々の Quality of Life の向上と効率的な医療経済の実現に寄与したいと考えています。
Read More
Fact Sheet
The biopharma industry is experiencing a paradigm shift in the outsourcing of regulatory affairs operations. In particular, this trend is being adopted by biopharma companies with marketed and mature products who are seeking strategic partners to manage their post-approval regulatory operations. In addition, emerging companies do not have substantial global resources to...
Read More
Article
Innovation is a vital part of drug development, and key to improved market access. Whilst generics are often the mainstay of the market, there are opportunities to create truly innovative therapeutics in other areas, including cell and gene therapies and biologics, as well as novel delivery systems and drug/device combinations. Small companies and university spinoffs...
Explore More
White Paper
Executing clinical studies using risk-based Monitoring (RBM) methodologies is reducing risks in clinical development, while improving patient safety and study quality. Clinical trial site engagement is critical to your study’s performance and ultimately, its success. Read this article to understand how your Investigator Sites can improve overall site performance; learn...
Explore More
Brochure
Learn how to transform your clinical development with Quintiles' risk-based monitoring solution - Data-driven Trial Execution.According to a 2016 study by the Tufts Center for the Study of Drug Development, for a single new drug, drug development costs can be $2.6B and take 10 years, with a significant portion of that cost attributed to trial operations.Regulatory bodies...
Read More
Press Release
DANBURY, CT and RESEARCH TRIANGLE PARK, NC, September 14, 2016 – IMS Health Holdings, Inc. (NYSE:IMS) today announced the pricing of its offering of $1.75 billion equivalent in gross proceeds of senior notes, consisting of $1.05 billion of U.S. Dollar notes and €625 million of Euro notes to be issued by its wholly owned subsidiary, IMS Health Incorporated. The offering...
Read More
Press Release
DANBURY, CT and RESEARCH TRIANGLE PARK, NC, September 12, 2016 – IMS Health Holdings, Inc. (NYSE:IMS) today announced that its wholly owned subsidiary, IMS Health Incorporated, intends to raise $1.5 billion equivalent in gross proceeds through an offering of senior notes. The company is planning to issue two separate tranches of notes, one in U.S. Dollars, due 2026, and...
Read More
Presentation
The adoption of risk-based monitoring (RBM) is both increasing and deepening, impacting the execution of clinical trials of all sizes and phases.  But much is required to ensure RBM studies go well, with roles and processes changing with innovative technology use. Download this webinar as Quintiles shares recent research results and our view of the status of RBM, along...
Explore More
Article
Risk-based monitoring (RBM) is transforming how clinical studies are being executed and managed. Clinical development is at a crossroads - it costs too much and takes too long to develop and bring new therapies to market. With support from the Food and Drug Administration, other global regulatory bodies and industry consortia, risk-based monitoring (RBM) is transforming...
Explore More
Press Release
DANBURY, CT and RESEARCH TRIANGLE PARK, NC, August 29, 2016 – IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational Holdings Inc. (NYSE:Q) today announced key senior management roles in the future Quintiles IMS corporate leadership team, subject to the completion of the merger.Senior functional leaders reporting to Chairman and Chief Executive Officer Ari...
Read More
White Paper
This white paper discusses partnering solutions that are specifically tailored for emerging biopharma. Given tremendous advances in this segment of the overall biopharmaceutical market, even though each company may only have one or two assets, the total pipeline is equivalent to roughly two-thirds of the entire global industry pipeline.Emerging biopharma is well served by...
Explore More
White Paper
Medical device makers are bullish about the future in general and about Asia-Pacific in particular. With a current commercial market size of USD $55 billion to $60 billion1,2, the region is a hot spot for medical device companies worldwide for sales, investment and expansion.This paper looks at the factors behind the attractiveness of Asia-Pacific for medical device...
Explore More
Fact Sheet
Today’s biosimilar landscape is characterized by rapid growth, intense competition, a diverse set of challenges, and large opportunities. As originator biologics go off patent, biotech companies are developing biosimilars to capture their share of a lucrative market. Sponsors aiming to capitalize on “first mover” advantages in major markets need an experienced partner...
Read More
Presentation
Learn more about Quintiles presentations and posters at ICPE 2016.
Explore More
Presentation
Learn more about our pre-conference activities at ICPE 2016.
Explore More
Presentation
As an investigational compound progresses from early phase randomized clinical trials to being approved for prescribing to patients in physician practice, the research focus shifts from ‘Does the drug work’ to ‘Does the drug work in real world settings?’ Ideally, data collection on observational study designs should reflect standard of practice care at physician visits...
Explore More